Xalkori (crizotinib) — Medica
Inflammatory Myofibroblastic Tumor (ALK-positive)
Initial criteria
- age ≥ 1 year
- disease is anaplastic lymphoma kinase (ALK)-positive
- EITHER patient has advanced, recurrent, or metastatic disease OR tumor is inoperable
Approval duration
1 year